Ozagrel Sodium for Injection
Function and Efficacy
This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats.
Ingredients
Ozagrel sodium.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| Ozagrel sodiumIngredients |
This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats. More |
189224-26-8 | 10 |
Indication
It is suitable for the treatment of acute thrombotic cerebral infarction and movement disorders associated with cerebral infarction.
Usage and Dosage
Adults: 40mg~80mg (2~4 vials) at a time, 1~2 times a day, dissolved in 500ml of normal saline or 5% glucose solution, continuous intravenous drip, 2 weeks as a course of treatment.
Adverse Reactions
Gastrointestinal reactions and allergic reactions, such as nausea, vomiting, urticaria, rash, etc., are relieved after appropriate treatment. A few cases may experience increased GPT and BUN, intracranial, gastrointestinal, subcutaneous bleeding, and thrombocytopenia.
Precautions
1. It is contraindicated for patients with hemorrhagic cerebral infarction or deep coma due to large-area cerebral infarction; 2. It is contraindicated for patients with severe heart, lung, liver, and kidney dysfunction, such as severe arrhythmia and myocardial infarction; 3. It is contraindicated for patients with blood diseases or bleeding tendency; 4. It is contraindicated for patients with severe hypertension, with systolic blood pressure exceeding 26.6kpa (i.e., above 200 mmHg); 5. It should be used with caution by patients who are allergic to this product and pregnant women.
Special Population Medication
Precautions during pregnancy and lactation: Use with caution in pregnant women.
Drug Interactions
Avoid mixing with calcium-containing infusions.
Storage
Keep away from light and store in a sealed container.
Packaging Specification
20mg (as ozagrel sodium)
Manufacturer
Yabao Pharmaceutical Group Co., Ltd.
-
Founded in:
1999-01-26 -
Address:
No. 43, Fumin Road, Ruicheng County, Yuncheng City, Shanxi Province -
Tax NO.:
91140000701108049W -
Registered Funds:
720,000,940 yuan -
Website:
-
Email: